A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus Ribavirin for HCV Genotype-1 Patients
Evaluation of Unipeg® for Response and Ongoing Safety in Pakistani Population
EXtended Therapy in Hepatitis C Genotype 3 Infected Patients
Peginterferon Alfa-2a and Ribavirin for Genotype 2 Chronic Hepatitis C: Duration and Ribavirin Dose Stratified by RVR
Early Prediction of Successful Treatment for Chronic Hepatitis C Virus Infection in Taiwan
Randomized Trial of 24 or 48 Weeks of Peginterferon Alfa-2a Plus Ribavirin for HCV Genotype 1-infected Patients
† Study has passed its completion date and status has not been verified in more than two years.